You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLOFARABINE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for clofarabine and what is the scope of freedom to operate?

Clofarabine is the generic ingredient in two branded drugs marketed by Abon Pharms Llc, Accord Hlthcare, Amneal, Dr Reddys, Eugia Pharma, Gland Pharma Ltd, Hospira, Meitheal, MSN, Mylan Labs Ltd, Novast Labs, and Genzyme, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for clofarabine. Twelve suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for CLOFARABINE
Drug Prices for CLOFARABINE

See drug prices for CLOFARABINE

Recent Clinical Trials for CLOFARABINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
John Horan, MDPhase 1/Phase 2
GlycoMimetics IncorporatedPhase 1/Phase 2
Vastra Gotaland RegionPhase 3

See all CLOFARABINE clinical trials

Generic filers with tentative approvals for CLOFARABINE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up20MG/20MLINJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for CLOFARABINE
Paragraph IV (Patent) Challenges for CLOFARABINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CLOLAR Injection clofarabine 1 mg/mL, 20 mL vial 021673 1 2012-02-23

US Patents and Regulatory Information for CLOFARABINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira CLOFARABINE clofarabine SOLUTION;INTRAVENOUS 210283-001 Dec 27, 2018 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abon Pharms Llc CLOFARABINE clofarabine SOLUTION;INTRAVENOUS 204029-001 May 9, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novast Labs CLOFARABINE clofarabine SOLUTION;INTRAVENOUS 210270-001 Sep 14, 2018 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Genzyme CLOLAR clofarabine SOLUTION;INTRAVENOUS 021673-001 Dec 28, 2004 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CLOFARABINE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme CLOLAR clofarabine SOLUTION;INTRAVENOUS 021673-001 Dec 28, 2004 ⤷  Sign Up ⤷  Sign Up
Genzyme CLOLAR clofarabine SOLUTION;INTRAVENOUS 021673-001 Dec 28, 2004 ⤷  Sign Up ⤷  Sign Up
Genzyme CLOLAR clofarabine SOLUTION;INTRAVENOUS 021673-001 Dec 28, 2004 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for CLOFARABINE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
ORPHELIA Pharma SAS Ivozall clofarabine EMEA/H/C/005039
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis.
Authorised yes no no 2019-11-14
Sanofi B.V. Evoltra clofarabine EMEA/H/C/000613
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis.
Authorised no no no 2006-05-29
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.